BR112018076229A2 - formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo - Google Patents
formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduoInfo
- Publication number
- BR112018076229A2 BR112018076229A2 BR112018076229-6A BR112018076229A BR112018076229A2 BR 112018076229 A2 BR112018076229 A2 BR 112018076229A2 BR 112018076229 A BR112018076229 A BR 112018076229A BR 112018076229 A2 BR112018076229 A2 BR 112018076229A2
- Authority
- BR
- Brazil
- Prior art keywords
- histidine
- urea
- individual
- treatment
- topical formulation
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract 2
- 206010013786 Dry skin Diseases 0.000 title 1
- 230000037336 dry skin Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001823 pruritic effect Effects 0.000 title 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010060875 Uraemic pruritus Diseases 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670438 | 2016-06-17 | ||
| DKPA201670438 | 2016-06-17 | ||
| DKPA201770225 | 2017-03-28 | ||
| DKPA201770225 | 2017-03-28 | ||
| PCT/DK2017/050201 WO2017215723A1 (en) | 2016-06-17 | 2017-06-16 | Formulation for use in the treatment of uremic pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018076229A2 true BR112018076229A2 (pt) | 2019-03-26 |
Family
ID=60663348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018076229-6A BR112018076229A2 (pt) | 2016-06-17 | 2017-06-16 | formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10806721B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3471720B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7019684B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102454777B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109414430B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017283511B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018076229A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3026620C (cg-RX-API-DMAC7.html) |
| ES (1) | ES3006940T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018146294A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017215723A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102454777B1 (ko) * | 2016-06-17 | 2022-10-14 | 드러그 딜리버리 솔루션즈 에이피에스 | 요독 가려움증의 치료에 사용하기 위한 제형 |
| WO2023194400A1 (en) * | 2022-04-06 | 2023-10-12 | Mc2 Therapeutics Ltd | Topical formulation for use in the treatment or prevention of itchy dry skin |
| EP4681722A1 (en) * | 2024-07-18 | 2026-01-21 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of inflammatory skin diseases with urocanase inhibitor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4025645A (en) | 1976-01-27 | 1977-05-24 | Jelenko Iii Carl | Non-steroid topical agent for alleviating inflammation in mammals |
| US5811446A (en) | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| US6573302B1 (en) | 1999-09-29 | 2003-06-03 | Medical Merchandising, Inc. | Cream utilizing capsaicin |
| US20060211754A1 (en) | 2005-03-16 | 2006-09-21 | Yu Ruey J | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof |
| US20070065396A1 (en) | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
| JP5168996B2 (ja) * | 2007-04-13 | 2013-03-27 | 味の素株式会社 | アミノ酸類高配合防腐水溶液 |
| FR2916351B1 (fr) | 2007-05-22 | 2012-12-07 | Galderma Res & Dev | Composition pharmaceutique comprenant au moins deux composes choisis parmi l'acide pyrrolidone-5-carboxylique, la citrulline, l'arginine et l'asparagine et leur utilisation dans le traitement de la dermatite atopique |
| US20090017129A1 (en) | 2007-07-13 | 2009-01-15 | Ma Or Ze Ev | Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof |
| US8337820B2 (en) | 2008-02-13 | 2012-12-25 | Bart Nieuwenhuijsen | Composition of a water-soluble sunscreen preparation for acne rosacea |
| GB0803054D0 (en) | 2008-02-20 | 2008-03-26 | Univ Manchester | Medicament |
| EP2373583A1 (en) | 2008-07-23 | 2011-10-12 | Fze Engsl | A combined solid waste, carbon dioxide quicklime sparging, brine water, and reverse osmosis/ion exchange processes for the production of soda chemicals |
| FR2938193B1 (fr) * | 2008-11-07 | 2011-08-12 | Expanscience Lab | Medicament ou composition dermatologique comprenant un extrait peptidique d'avocat destine au traitement et a la prevention du prupit |
| NZ595775A (en) | 2008-12-26 | 2013-07-26 | Glenmark Pharmaceuticals Sa | Fused imidazole derivatives as trpv3 antagonist |
| KR100953515B1 (ko) * | 2009-08-28 | 2010-04-21 | 전북대학교산학협력단 | 피부 가려움증 개선을 위한 조성물 |
| DE102011110909A1 (de) * | 2011-08-18 | 2013-02-21 | Paul Hartmann Ag | Zusammensetzungen mit einer die Hautbarriere verbessernden Wirkstoffkombination |
| EP2869897A4 (en) * | 2012-07-06 | 2016-09-28 | Univ Duke | ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ |
| US20160008297A1 (en) | 2012-08-23 | 2016-01-14 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) |
| CN103908467B (zh) * | 2013-01-05 | 2017-02-08 | 西藏博睿生物科技有限公司 | 一种药物组合物及制剂 |
| WO2016086280A1 (pt) * | 2014-12-04 | 2016-06-09 | Cardoso De Gouveia Alberto | Composição dermatológica e seu uso |
| KR102454777B1 (ko) | 2016-06-17 | 2022-10-14 | 드러그 딜리버리 솔루션즈 에이피에스 | 요독 가려움증의 치료에 사용하기 위한 제형 |
-
2017
- 2017-06-16 KR KR1020197000483A patent/KR102454777B1/ko active Active
- 2017-06-16 ES ES17812796T patent/ES3006940T3/es active Active
- 2017-06-16 CN CN201780042643.4A patent/CN109414430B/zh active Active
- 2017-06-16 AU AU2017283511A patent/AU2017283511B2/en active Active
- 2017-06-16 EP EP17812796.5A patent/EP3471720B1/en active Active
- 2017-06-16 RU RU2018146294A patent/RU2018146294A/ru unknown
- 2017-06-16 KR KR1020247020977A patent/KR20240100484A/ko not_active Ceased
- 2017-06-16 JP JP2019518350A patent/JP7019684B2/ja active Active
- 2017-06-16 EP EP24178043.6A patent/EP4397368A3/en active Pending
- 2017-06-16 BR BR112018076229-6A patent/BR112018076229A2/pt not_active Application Discontinuation
- 2017-06-16 CA CA3026620A patent/CA3026620C/en active Active
- 2017-06-16 US US16/310,025 patent/US10806721B2/en active Active
- 2017-06-16 WO PCT/DK2017/050201 patent/WO2017215723A1/en not_active Ceased
- 2017-06-16 CN CN202211256647.1A patent/CN115671098A/zh active Pending
- 2017-06-16 KR KR1020227035218A patent/KR20220143149A/ko not_active Ceased
-
2020
- 2020-04-27 AU AU2020202785A patent/AU2020202785B2/en active Active
- 2020-09-18 US US17/025,548 patent/US20210000796A1/en not_active Abandoned
-
2022
- 2022-02-02 JP JP2022014925A patent/JP7220316B2/ja active Active
- 2022-10-28 JP JP2022173435A patent/JP2022187022A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020202785A1 (en) | 2020-05-14 |
| EP3471720B1 (en) | 2024-12-04 |
| EP4397368A2 (en) | 2024-07-10 |
| CA3026620C (en) | 2022-09-20 |
| KR20220143149A (ko) | 2022-10-24 |
| US20210000796A1 (en) | 2021-01-07 |
| US10806721B2 (en) | 2020-10-20 |
| ES3006940T3 (en) | 2025-03-19 |
| RU2018146294A3 (cg-RX-API-DMAC7.html) | 2020-09-08 |
| KR20240100484A (ko) | 2024-07-01 |
| RU2018146294A (ru) | 2020-07-17 |
| CN109414430A (zh) | 2019-03-01 |
| JP2022187022A (ja) | 2022-12-15 |
| CA3026620A1 (en) | 2017-12-21 |
| WO2017215723A1 (en) | 2017-12-21 |
| EP3471720C0 (en) | 2024-12-04 |
| JP2022048311A (ja) | 2022-03-25 |
| EP3471720A1 (en) | 2019-04-24 |
| EP3471720A4 (en) | 2020-02-05 |
| JP7220316B2 (ja) | 2023-02-09 |
| JP2019518084A (ja) | 2019-06-27 |
| AU2017283511A1 (en) | 2019-01-17 |
| EP4397368A3 (en) | 2024-10-16 |
| US20190321336A1 (en) | 2019-10-24 |
| JP7019684B2 (ja) | 2022-02-15 |
| KR102454777B1 (ko) | 2022-10-14 |
| AU2017283511B2 (en) | 2020-02-06 |
| CN109414430B (zh) | 2022-11-01 |
| CN115671098A (zh) | 2023-02-03 |
| AU2020202785B2 (en) | 2022-02-24 |
| KR20190020022A (ko) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4374851A3 (en) | Ophthalmic composition for treatment of dry eye disease | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| MX2020001083A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| BR112016000335A8 (pt) | método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica | |
| EA201892493A1 (ru) | Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
| BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
| PH12018500817B1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| MX2018011082A (es) | Péptido o aminoácido n-lipoico, derivados y sus usos. | |
| FI4000628T3 (fi) | Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle | |
| EP4397368A3 (en) | Formulation for use in the treatment of uremic pruritus | |
| BR112015030734A2 (pt) | produto farmacêutico, kit e método de tratamento | |
| BR112018067663A2 (pt) | compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos | |
| BR112018008556A2 (pt) | ?composições farmacêuticas e métodos para tratar ictiose congênita? | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |